In vivo IFNγ stimulation can substantially elevate tumor PD-L1 expression, confounding the assessment of therapeutic efficacy and selection of antibody drugs based on PD-L1 and other tumor factors used as immune checkpoint inhibitors in clinical settings. Here, CD274 is linked to neoplasm.